Vantage Biosciences

Vantage Biosciences is a private, clinical-stage biotech developing an oral AOC-3 inhibitor for inflammatory conditions, with a primary focus on non-proliferative diabetic retinopathy (NPDR). The company is preparing to advance its lead candidate into a Phase 2 clinical trial and is based in London. Its strategy involves intervening early in disease biology to provide disease-modifying therapy, and it is actively seeking collaborations to expand its network and team.

Oral small-molecule inhibitors targeting AOC-3/VAP-1 to modulate leukocyte trafficking and reduce oxidative stress, aiming for disease-modifying effects in inflammation.

Competition includes established intraocular anti-VEGF injections (e.g., ranibizumab, aflibercept) for advanced disease, but these are not used in NPDR. Other companies are exploring oral therapies for diabetic retinopathy targeting different pathways (e.g., PKC inhibitors, integrin antagonists). Vantage's differentiation lies in its specific AOC-3 mechanism aimed at the earliest inflammatory drivers.